Liver disease affects hundreds of millions globally, yet clinicians have long debated which non-invasive tools best replace the painful, costly, and sampling-error-prone liver biopsy. A landmark prospective validation study now provides the clearest head-to-head evidence to date — and the answer is not one-size-fits-all.
The LITMUS Imaging Study, published in Nature Medicine, enrolled a prospectively followed cohort to compare serum-based biomarker panels against multiple imaging modalities — including elastography techniques such as magnetic resonance elastography and vibration-controlled transient elastography — for two distinct diagnostic tasks: identifying metabolic dysfunction-associated steatohepatitis (MASH) and staging liver fibrosis severity. The core finding bifurcates cleanly by clinical question: serum biomarkers demonstrated superior diagnostic accuracy for detecting active steatohepatitis (the inflammatory, hepatocyte-damaging phase that drives disease progression), while elastography-based imaging outperformed blood tests when the clinical priority shifted to quantifying advanced fibrosis and cirrhosis. No single modality dominated across both tasks.
This result carries considerable practical weight. MASH and advanced fibrosis represent two different clinical decision points — the first determines eligibility for emerging pharmacological therapies such as resmetirom, while the second drives surveillance and transplant planning. The LITMUS findings suggest that optimal clinical pathways may require sequential or complementary testing rather than defaulting to a single preferred tool. The study's prospective design and multi-centre execution give these results considerably more evidentiary weight than prior cross-sectional or retrospective biomarker studies. Key limitations include the degree to which the enrolled cohort reflects real-world clinical heterogeneity, and whether specific serum panels tested are widely accessible across healthcare systems. Overall, this is a genuinely practice-informing finding that directly challenges current single-modality diagnostic approaches in MASLD management.